Get started
Author

Amy DuPage

Observed name: A.G. DuPage
ORCID: 0000-0003-1491-085X
Observed ORCID: 0000-0003-1491-085X
OpenAlex ID: A5007738342
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
2022 · Shweta Singh, Laura Serwer, et al. · Molecular Cancer Therapeutics · 46
PDF
Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial
2025 · Yelena Y. Janjigian, Do-Youn Oh, et al. · Nature Medicine · 30
PDF
Abstract C165: Development of a probody drug conjugate (PDC) against CD166 for the treatment of multiple cancers
2015 · Annie Yang Weaver, Shweta Singh, et al. · Molecular Cancer Therapeutics · 10
Abstract B116: Optimizing a CD71-targeting Probody drug conjugate (PDC) for activity in multiple solid tumor and lymphoma models and for tolerability in nonhuman primates
2018 · Shweta Singh, Laura Serwer, et al. · Molecular Cancer Therapeutics · 8
Abstract 2975: Development of a probody drug conjugate (PDC) targeting CD71 for the treatment of solid tumors and lymphomas
2016 · Shweta Singh, Amy DuPage, et al. · Cancer Research · 7
2112MO Domvanalimab (dom), zimberelimab (zim), and FOLFOX in first-line (1L) advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma (GC/GEJC/EAC): 26-month update from EDGE-Gastric, arm A1
2025 · S.Y. Rha, D-Y. Oh, et al. · Annals of Oncology
Supplementary Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
2023 · Shweta Singh, Laura Serwer, et al.
PDF
Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
2023 · Shweta Singh, Laura Serwer, et al.
Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
2023 · Shweta Singh, Laura Serwer, et al.
Works count: 9
Citation count: 101
H-index: 5
I10-index: 3
Year
Topic
Type